The use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy

Typeset version

 

TY  - JOUR
  - Tangney, M.,van Pijkeren, J. P.,Gahan, C. G.
  - 2010
  - July
  - The use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy
  - Validated
  - ()
  - 1
  - 44
  - 284
  - 7284
  - Listeria monocytogenes is an intracellular pathogen that lyses the phagosomal vacuole of infected cells, proliferates in the host cell cytoplasm and can actively enter adjacent cells. The pathogen is therefore well suited to exploitation as a vector for the delivery of DNA to target cells as the lifecycle favors cellular targeting with vector amplification and the potential for cell-to-cell spread. We have recently demonstrated DNA transfer by L. monocytogenes in growing tumors in murine models. Our approach exploited an ampicillin sensitive stain of L. monocytogenes which can be lysed through systemic administration of ampicillin to facilitate release of plasmid DNA for expression by infected mammalian cells. Here, we discuss the implications of this technology and the potential for future improvements of the system.Listeria monocytogenes is an intracellular pathogen that lyses the phagosomal vacuole of infected cells, proliferates in the host cell cytoplasm and can actively enter adjacent cells. The pathogen is therefore well suited to exploitation as a vector for the delivery of DNA to target cells as the lifecycle favors cellular targeting with vector amplification and the potential for cell-to-cell spread. We have recently demonstrated DNA transfer by L. monocytogenes in growing tumors in murine models. Our approach exploited an ampicillin sensitive stain of L. monocytogenes which can be lysed through systemic administration of ampicillin to facilitate release of plasmid DNA for expression by infected mammalian cells. Here, we discuss the implications of this technology and the potential for future improvements of the system.
  - 1949-1026 (Electronic) 19
  - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=21327062http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=21327062
DA  - 2010/07
ER  - 
@article{V89608409,
   = {Tangney,  M. and van Pijkeren,  J. P. and Gahan,  C. G. },
   = {2010},
   = {July},
   = {The use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy},
   = {Validated},
   = {()},
   = {1},
   = {44},
  pages = {284--7284},
   = {{Listeria monocytogenes is an intracellular pathogen that lyses the phagosomal vacuole of infected cells, proliferates in the host cell cytoplasm and can actively enter adjacent cells. The pathogen is therefore well suited to exploitation as a vector for the delivery of DNA to target cells as the lifecycle favors cellular targeting with vector amplification and the potential for cell-to-cell spread. We have recently demonstrated DNA transfer by L. monocytogenes in growing tumors in murine models. Our approach exploited an ampicillin sensitive stain of L. monocytogenes which can be lysed through systemic administration of ampicillin to facilitate release of plasmid DNA for expression by infected mammalian cells. Here, we discuss the implications of this technology and the potential for future improvements of the system.Listeria monocytogenes is an intracellular pathogen that lyses the phagosomal vacuole of infected cells, proliferates in the host cell cytoplasm and can actively enter adjacent cells. The pathogen is therefore well suited to exploitation as a vector for the delivery of DNA to target cells as the lifecycle favors cellular targeting with vector amplification and the potential for cell-to-cell spread. We have recently demonstrated DNA transfer by L. monocytogenes in growing tumors in murine models. Our approach exploited an ampicillin sensitive stain of L. monocytogenes which can be lysed through systemic administration of ampicillin to facilitate release of plasmid DNA for expression by infected mammalian cells. Here, we discuss the implications of this technology and the potential for future improvements of the system.}},
  issn = {1949-1026 (Electronic) 19},
   = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=21327062http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=21327062},
  source = {IRIS}
}
AUTHORSTangney, M.,van Pijkeren, J. P.,Gahan, C. G.
YEAR2010
MONTHJuly
JOURNAL_CODE
TITLEThe use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORD
VOLUME1
ISSUE44
START_PAGE284
END_PAGE7284
ABSTRACTListeria monocytogenes is an intracellular pathogen that lyses the phagosomal vacuole of infected cells, proliferates in the host cell cytoplasm and can actively enter adjacent cells. The pathogen is therefore well suited to exploitation as a vector for the delivery of DNA to target cells as the lifecycle favors cellular targeting with vector amplification and the potential for cell-to-cell spread. We have recently demonstrated DNA transfer by L. monocytogenes in growing tumors in murine models. Our approach exploited an ampicillin sensitive stain of L. monocytogenes which can be lysed through systemic administration of ampicillin to facilitate release of plasmid DNA for expression by infected mammalian cells. Here, we discuss the implications of this technology and the potential for future improvements of the system.Listeria monocytogenes is an intracellular pathogen that lyses the phagosomal vacuole of infected cells, proliferates in the host cell cytoplasm and can actively enter adjacent cells. The pathogen is therefore well suited to exploitation as a vector for the delivery of DNA to target cells as the lifecycle favors cellular targeting with vector amplification and the potential for cell-to-cell spread. We have recently demonstrated DNA transfer by L. monocytogenes in growing tumors in murine models. Our approach exploited an ampicillin sensitive stain of L. monocytogenes which can be lysed through systemic administration of ampicillin to facilitate release of plasmid DNA for expression by infected mammalian cells. Here, we discuss the implications of this technology and the potential for future improvements of the system.
PUBLISHER_LOCATION
ISBN_ISSN1949-1026 (Electronic) 19
EDITION
URLhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=21327062http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=21327062
DOI_LINK
FUNDING_BODY
GRANT_DETAILS